It is urgent for new treatment for type 2 diabetes strategies.
Some new approaches include:
Long-acting (E.g. once a week), peptide 1 receptor of post prandial improvement of insulin secretion, excessive production of glucagon and promotion of saturation decrease agonists of the glucagon-like
Inhibitor of Dipeptidylpeptidase Dipeptidyl peptidase 4 (DPP-4), which has the effect of strengthening the endogenous Incretin hormones
Inhibitors of the sodium glucose Kotransporter, to increase the renal elimination of glucose
Inhibitors of 11beta,21-dihydroxypregna-1,4,16-triene-3,20-Dione-hydroxysteroid dehydrogenase 1, the effects of glucocorticoids on liver and fat reduction
-Insulina Liberación Glucokinase activators and pancreatic-g - acid protein-bound Grasos acido receptor agonists, antagonists of glucagon receptors and metabolic inhibitors of liver glucose production are also being studied.
Figure 1 action for the DPP-4 inhibitor. Please note that inactive normal DPP-4 of GLP-1. DPP-4 inhibitors block DPP-4, which in turn, GLP-1 active until late. Click on the image for a larger view. Made with ●capacitar. The Charter of action of DPP-4 inhibitors is now in Wikipedia.
References:
Management of type 2 diabetes: new and future advances in treatment. The Lancet, volume 378 9786-, s. 182-197, July 9, 2011.
Google + comments:
Are Emily-Lu-a question many these treatments by minorities, the higher prevalence of diabetes?
VES DIMOV good question. See also: "for the year 2030 the number of people with diabetes around the world should rise up to 500 million ($ 470 billion) - nearly 80% of them are in countries with low income and middle income countries." In these regions insulin and drugs for the treatment of diabetes often not accessible or are too expensive." Nutrition of early intervention can be the answer for type 2 diabetes.
Emily - Lu "early dietary interventions may be the answer to type 2 diabetes." this is correct, but much easier said this fact. I think in general basic education of the patient.
VES DIMOV diet is difficult to apply from the perspective of the patient. Activity was not the expected in the most recent study reported in the July, 2011 edition of "The Lancet" use magazine.
Some new approaches include:
Long-acting (E.g. once a week), peptide 1 receptor of post prandial improvement of insulin secretion, excessive production of glucagon and promotion of saturation decrease agonists of the glucagon-like
Inhibitor of Dipeptidylpeptidase Dipeptidyl peptidase 4 (DPP-4), which has the effect of strengthening the endogenous Incretin hormones
Inhibitors of the sodium glucose Kotransporter, to increase the renal elimination of glucose
Inhibitors of 11beta,21-dihydroxypregna-1,4,16-triene-3,20-Dione-hydroxysteroid dehydrogenase 1, the effects of glucocorticoids on liver and fat reduction
-Insulina Liberación Glucokinase activators and pancreatic-g - acid protein-bound Grasos acido receptor agonists, antagonists of glucagon receptors and metabolic inhibitors of liver glucose production are also being studied.
Figure 1 action for the DPP-4 inhibitor. Please note that inactive normal DPP-4 of GLP-1. DPP-4 inhibitors block DPP-4, which in turn, GLP-1 active until late. Click on the image for a larger view. Made with ●capacitar. The Charter of action of DPP-4 inhibitors is now in Wikipedia.
References:
Management of type 2 diabetes: new and future advances in treatment. The Lancet, volume 378 9786-, s. 182-197, July 9, 2011.
Google + comments:
Are Emily-Lu-a question many these treatments by minorities, the higher prevalence of diabetes?
VES DIMOV good question. See also: "for the year 2030 the number of people with diabetes around the world should rise up to 500 million ($ 470 billion) - nearly 80% of them are in countries with low income and middle income countries." In these regions insulin and drugs for the treatment of diabetes often not accessible or are too expensive." Nutrition of early intervention can be the answer for type 2 diabetes.
Emily - Lu "early dietary interventions may be the answer to type 2 diabetes." this is correct, but much easier said this fact. I think in general basic education of the patient.
VES DIMOV diet is difficult to apply from the perspective of the patient. Activity was not the expected in the most recent study reported in the July, 2011 edition of "The Lancet" use magazine.
Anda baru saja membaca artikel yang berkategori diabetes /
treatments
dengan judul New treatments for type 2 diabetes. Anda bisa bookmark halaman ini dengan URL https://medicalandhealthblogz.blogspot.com/2014/06/new-treatments-for-type-2-diabetes.html. Terima kasih!
Ditulis oleh:
Unknown - Friday, June 13, 2014
Belum ada komentar untuk "New treatments for type 2 diabetes"
Post a Comment